Document:

Document

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.
Exhibit 10.16
AMENDMENT NO. 6 TO
AGREEMENT

THIS AMENDMENT NO.6 TO AGREEMENT (this “Amendment”) is made effective as of September 1, 2021, between IDEXX Europe B.V., a corporation organized under the law of the Netherlands (“IDEXX”) and Ortho-Clinical Diagnostics, Inc., a New York corporation with offices at 100 Indigo Creek Drive, Rochester, New York, U.S.A. (“OCD” or “Ortho”; each of IDEXX and Ortho also a “Party” and together also the “Parties”). 
WHEREAS, Ortho and IDEXX have entered into that certain agreement dated as of October 17, 2003 (such agreement, as amended by Amendment No. 1 thereto effective January 1, 2005, Amendment No. 2 thereto effective January 18, 2008, Amendment No. 3 thereto effective December 28, 2011, Amendment No. 4 thereto effective December 9, 2013, Amendment No. 5 thereto effective July 9, 2019 (as so amended, the “Agreement”), regarding supply by Ortho of dry slides for IDEXX veterinary chemistry analyzers; and 
WHEREAS, the Parties now desire to update the annual Product forecast and price true-up processes, and agree to amend the Agreements accordingly;
NOW THEREFORE, in consideration of the mutual promises, covenants and agreements hereinafter set forth, the Parties hereby agree as follows:
1.The first and second paragraph of Section 5.04 shall be deleted in their entirety and replaced as follows:

“No later than [**] of each year, IDEXX shall provide Ortho with its notice of aggregate forecasted purchase volume and mix of Products (on a Product SKU level) for [**] of the subsequent [**] for each of the VETTEST slides (single slides and PANELS/PROFILES slides for the VETTEST Analyzer and New Slides) (the “Initial Forecast”).  Ortho shall review the Initial Forecast. In the event that Ortho considers, in good faith, that the Initial Forecast is outside of its manufacturing capability for the [**] allocations specified for each of the VETTEST slides (due to Ortho’s total manufacturing capacity, Product mix (including on a Product SKU level) or otherwise), Ortho will provide documented acknowledgement of the limitation and the Parties will agree to discuss solutions for provision of slide volume to meet IDEXX’s forecasted requirements (including any changes to the quarterly allocation of the Product volume or mix of Products, or the overall Product volume).  Any resulting mutually agreed updates shall be incorporated in writing into the Initial Forecast, which shall be deemed the “Annual Purchase Forecast”. If Ortho does not provide such acknowledgement by the [**] following the Initial Forecast, the Initial Forecast shall be deemed within Ortho’s capability for production, and shall be deemed the Annual Purchase Forecast.  As long as the [**] slide 

order volumes for the [**] do not exceed [**] Ortho shall deliver the slides in accordance with IDEXX’s orders.  In the event an IDEXX order is outside of Ortho’s capacity limitation due to the mix of Products, Ortho shall notify IDEXX and the Parties shall discuss in good faith an amicable solution that reflects both Ortho’s capacity limitations and IDEXX’s order.

The [**] constitute non-binding forecasts for Ortho’s planning purposes and shall also be the basis for determining estimated slide pricing pursuant to Section 7.03 below.”

2.Section 5.05 shall be deleted in its entirety and replaced as follows:

“In the event IDEXX intends to place a purchase order for Products that exceeds [**] of the [**] (“Excess Order”), IDEXX will notify Ortho thereof at least two (2) weeks in advance of the Excess Order.  Within one (1) week following receipt of such request, Ortho will review and notify IDEXX of the extent of its ability to so supply the Excess Order.   Ortho shall use best efforts to deliver the Excess Order, provided that, if such Excess Order exceeds its manufacturing capability (due to either Ortho’s total manufacturing capacity, Product mix or otherwise, in each case within the quarterly and annual term specified), the Parties will enter into good faith discussions to find solutions for provision of slide volume to meet the Excess Order, but a failure by Ortho to manufacture the Excess Order shall not constitute a breach of contract by Ortho.”

3.Section 7.02(b) shall be modified as follows:  The fifth paragraph (i.e., the paragraph that starts with “Within [**]...”) of Section 7.02(b) shall be deleted in its entirety and replaced as follows:

“(i)     [**]  

(ii)     [**].”

4.Except as modified by this Amendment, the Agreement remains in effect.  This Amendment is to be construed as part of the Agreement.  Each reference to “hereof”, “hereunder”, “herein” and “hereby” and each other similar reference and each reference to “this Agreement” and each other similar reference contained in the Agreement shall from and after the date set forth above, refer to the Agreement as amended hereby.
5.This Amendment may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.
*****

IN WITNESS WHEREOF and intending to be legally bound, the parties hereto have caused this Amendment to be duly executed in duplicate by their respective authorized representatives as of the day and year first written above:
ORTHO-CLINICAL DIAGNOSTICS, INC.        IDEXX EUROPE B.V. 
By: _/s/ Michael S. Iskara                By: /s/ Lily J. Lu
Name: Michael S. Iskara                Name: Lily J. Lu
Title: EVP  Commercial Excellence and Strategy    Title: Managing Director
Date: Nov 17, 2021                    Date: Nov 2, 2021

Acknowledged and consented to, solely as guarantor pursuant to Section 30 of the Agreement:
    
IDEXX LABORATORIES, INC.
By: /s/ John Hart
Name: John Hart
Title: Senior Vice President
Date: Nov 5, 2012

 [**] Text omitted throughout this exhibit for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.Document

Exhibit 10.19

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE
COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

November 2, 2021

IDEXX Laboratories, Inc. 
One IDEXX Drive 
Westbrook, ME 04091 

ATTN: John Hart
Corporate VP Worldwide Operations
IDEXX Laboratories, Inc.

Subject: Catalyst Capacity – Work Center 5 Project Approval 

Dear John: 

Reference is made to the agreement between Ortho-Clinical Diagnostics, Inc. (“Ortho”) and IDEXX Operations, Inc. (“IDEXX”) dated October 16, 2003 (such agreement as later amended from time to time (including subsequent amendments) the “Agreement”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Agreement.

In the past, Ortho retained a third-party company called [**] for the manufacture and sale to Ortho of manufacture lines used for the production of certain veterinary diagnostics slides at Ortho’s facility in Rochester, State of New York.  As Ortho manufactures and sells such slides to IDEXX, IDEXX reimbursed Ortho [**] of Ortho’s spend for such production lines with [**]. 

Ortho and IDEXX agreed that IDEXX’ increased demand for veterinary diagnostics slides is best addressed by constructing a new manufacturing line (“Catalyst Work Center 5”) instead of improving key assemblies of one of the existing manufacturing lines.

Following a competitive bid process (which solicited bids from [**] and [**]), Ortho and IDEXX agreed on June 9, 2021 to retain [**] for the manufacture and sale of Catalyst Work Center 5 by [**] to Ortho.

NOW, THEREFORE, in consideration of the mutual promises, covenants and agreements hereinafter set forth, the parties hereto agree as follows (this letter agreement the “Letter Agreement”):

1.Agreement Between Ortho and [**]; Catalyst Work Center 5 Costs
[**].  The Catalyst Work Center 5 project plan, as agreed by [**], is set forth in Exhibit A to this Letter Agreement.

Ortho and IDEXX agree to equally share the costs for the Catalyst Work Center 5 (the “Catalyst Work Center 5 Costs”).  The Catalyst Work Center 5 Costs consist of (i) “[**] Specific Costs”, which are actually incurred by Ortho under the Catalyst Work Center 5 Agreement, and (ii) “[**] Costs”, which are actually incurred by Ortho in relation to the Catalyst Work Center 5 from [**].
Ortho Clinical Diagnostics  |  100 Indigo Creek Drive Rochester, NY 14650

Catalyst Work Center 5 Cost estimates are set forth in Exhibit A.  Any savings below the anticipated      $[**] [**] Specific Costs specified in the Exhibit A and the Catalyst Work Center 5 Agreement will be shared [**] between the parties.  The parties agree to work together in good faith to minimize any costs in excess of the anticipated $[**] [**] Specific Costs as well as estimated [**] Costs. 

2.Invoices and Payments 
 Ortho shall invoice IDEXX in respect to [**] Specific Costs and [**] Costs following Ortho’s receipt of invoice for payment from the relevant vendor. Ortho shall provide IDEXX adequate documentation (including all relevant invoices and itemized expenses sufficient to identify the costs) to support all invoiced costs.   

IDEXX shall pay all undisputed invoices within thirty (30) days following receipt of invoice conforming to the above requirements from Ortho.  

3.Relationship to Agreement 
Except as explicitly set forth otherwise herein, the terms of the Agreement shall continue to apply to this Letter Agreement. In case of any conflict between this Letter Agreement and the Agreement, this Letter Agreement shall prevail with regard to the Catalyst Work Center 5 Costs.

4.Entire Agreement  
This Letter Agreement and the Agreement constitute the entire understanding between the parties hereto with respect to the subject matter herein and no amendment or modification of its terms shall be valid or binding upon any party unless reduced to writing and signed by authorized representatives of the parties hereto.  

Upon IDEXX’s countersignature below, this Letter Agreement shall become effective and binding upon the Parties in accordance with its terms.
Kind regards,

_/s/ Marwan Fathallah_____________________________

Marwan Fathallah
Head Of Quality, Regulatory, Compliance, Clinical & Medical Affairs • Quality Assurance & Quality Compliance
Ortho Clinical Diagnostics
100 Indigo Creek Drive
Rochester, NY 14626

Accepted and Agreed:

IDEXX Operations, Inc.

By:___/s/ John Hart_____________________________________________

Title:___Senior Vice President____________________________________

Date:___December 17, 2021______________________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}]]